Aliases & Classifications for Migraine with Aura

MalaCards integrated aliases for Migraine with Aura:

Name: Migraine with Aura 12 6 43 15 17 71
Migraine with Typical Aura 71
Classic Migraine 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10024
ICD9CM 34 346.0
MeSH 43 D020325
NCIt 49 C117005
SNOMED-CT 67 4473006
ICD10 32 G43.1
UMLS 71 C0154723 C1735856

Summaries for Migraine with Aura

Disease Ontology : 12 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary : Migraine with Aura, also known as migraine with typical aura, is related to migraine, familial hemiplegic, 1 and familial hemiplegic migraine, and has symptoms including headache An important gene associated with Migraine with Aura is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are cAMP signaling pathway and Synaptic vesicle cycle. The drugs Norepinephrine and Levomilnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and endothelial, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Migraine with Aura

Diseases in the Migraine with Aura family:

Migraine with Aura 7 Migraine with Aura 9

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 migraine, familial hemiplegic, 1 33.8 SLC6A4 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
2 familial hemiplegic migraine 33.7 SCN1A PRRT2 NOTCH3 KCNK18 CACNA1A ATP1A2
3 migraine with or without aura 1 33.4 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 MTHFR
4 migraine, familial hemiplegic, 3 33.2 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
5 migraine, familial hemiplegic, 2 33.2 SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
6 headache 32.4 SCN1A NOTCH3 KCNK18 CACNA1A ATP1A2
7 migraine without aura 32.2 SLC6A4 SCN1A NOTCH3 MTHFR KCNK18 FHL5
8 familial or sporadic hemiplegic migraine 32.0 SCN1A PRRT2 CACNA1A ATP1A2
9 patent foramen ovale 31.9 NOTCH3 MTHFR ATP1A2 ACE
10 sporadic hemiplegic migraine 31.5 SCN1A CACNA1A ATP1A2
11 restless legs syndrome 31.2 SLC6A4 SLC6A3 DRD2 CACNA1A
12 tic disorder 31.0 SLC6A4 SLC6A3 DRD2
13 epilepsy, idiopathic generalized 30.9 SCN1A PRRT2 CACNA1A ATP1A2
14 generalized anxiety disorder 30.8 SLC6A4 SLC6A3 HTR2C DRD2
15 status epilepticus 30.8 SCN1A DRD2 CACNA1A
16 mental depression 30.8 SLC6A4 SLC6A3 HTR2C HTR1B DRD2
17 mood disorder 30.7 SLC6A4 SLC6A3 HTR2C HTR1B DRD2 ACE
18 anxiety 30.6 SLC6A4 SLC6A3 HTR2C HTR1D HTR1B DRD2
19 major depressive disorder 30.5 SLC6A4 SLC6A3 MTHFR HTR2C HTR1D HTR1B
20 epilepsy 30.5 SLC6A3 SCN1A PRRT2 MTHFR FLNA CACNA1A
21 bipolar disorder 30.5 SLC6A4 SLC6A3 MTHFR HTR2C HTR1B DRD2
22 pure autonomic failure 30.1 DBH ACE
23 migraine with aura 7 12.7
24 migraine with aura 9 12.7
25 epilepsy, familial temporal lobe, 4 11.7
26 migraine with or without aura 13 11.7
27 familiar or sporadic hemiplegic migraine 11.4
28 episodic ataxia, type 5 10.7 SCN1A CACNA1A ATP1A2
29 hemiplegia 10.7 SCN1A CACNA1A ATP1A2
30 spinocerebellar ataxia 6 10.7 SCN1A CACNA1A ATP1A2
31 episodic ataxia, type 2 10.7 SCN1A CACNA1A ATP1A2
32 torticollis 10.7 PRRT2 DRD2 CACNA1A
33 intermittent explosive disorder 10.7 SLC6A4 HTR2C DRD2
34 inhibited male orgasm 10.7 SLC6A4 SLC6A3 HTR2C
35 infancy electroclinical syndrome 10.6 SCN1A PRRT2 ATP1A2
36 benign familial infantile epilepsy 10.6 SCN1A PRRT2 CACNA1A ATP1A2
37 electroclinical syndrome 10.6 SCN1A PRRT2 CACNA1A
38 episodic ataxia 10.6 SCN1A PRRT2 CACNA1A ATP1A2
39 alternating hemiplegia of childhood 10.6 SCN1A PRRT2 CACNA1A ATP1A2
40 psychosexual disorder 10.6 SLC6A4 HTR2C HTR1B
41 amphetamine abuse 10.6 SLC6A4 SLC6A3 HTR1B
42 delusional disorder 10.6 SLC6A3 HTR2C DRD2
43 generalized epilepsy with febrile seizures plus 10.6 SCN1A PRRT2 CACNA1A ATP1A2
44 impulse control disorder 10.6 SLC6A4 SLC6A3 DRD2
45 avoidant personality disorder 10.6 SLC6A4 SLC6A3 HTR1B
46 epileptic encephalopathy, early infantile, 6 10.6 SCN1A PRRT2 CACNA1A ATP1A2
47 pyromania 10.6 HTR1B DRD2
48 lingual-facial-buccal dyskinesia 10.6 SLC6A3 HTR2C DRD2
49 arteritic anterior ischemic optic neuropathy 10.6 MTHFR ACE
50 pathological gambling 10.6 SLC6A4 SLC6A3 DRD2 DBH

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to Migraine with Aura

Symptoms & Phenotypes for Migraine with Aura

UMLS symptoms related to Migraine with Aura:


headache

MGI Mouse Phenotypes related to Migraine with Aura:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
2 growth/size/body region MP:0005378 10.22 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
3 endocrine/exocrine gland MP:0005379 10.13 ACE CACNA1A DBH DRD2 FHL5 HTR1B
4 mortality/aging MP:0010768 10.13 ACE ATP1A2 CACNA1A DBH DRD2 FLNA
5 integument MP:0010771 10.02 ATP1A2 CACNA1A DBH DRD2 HTR2C MTHFR
6 nervous system MP:0003631 9.97 ATP1A2 CACNA1A DBH DRD2 FLNA HTR2C
7 muscle MP:0005369 9.86 ATP1A2 CACNA1A DRD2 HTR1B HTR2C NOTCH3
8 normal MP:0002873 9.65 ATP1A2 CACNA1A DBH DRD2 FLNA HTR1D
9 reproductive system MP:0005389 9.36 ACE CACNA1A DRD2 FHL5 FLNA HTR1B

Drugs & Therapeutics for Migraine with Aura

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Almotriptan Approved, Investigational Phase 4 181183-52-8, 154323-57-6 123606
9
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
10 Psychotropic Drugs Phase 4
11 Antidepressive Agents Phase 4
12 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
13 Hypoglycemic Agents Phase 4
14 Anticonvulsants Phase 4
15 Gastrointestinal Agents Phase 4
16 Anesthetics Phase 4
17 Serotonin Receptor Agonists Phase 4
18 Antiemetics Phase 4
19 Neurotransmitter Agents Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Analgesics Phase 4
23 Antirheumatic Agents Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Dopamine Agents Phase 4
27 Pharmaceutical Solutions Phase 4
28 Dopamine Antagonists Phase 4
29 Narcotics Phase 4
30 Analgesics, Opioid Phase 4
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 Ketorolac Tromethamine Phase 4
34
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
35
Promethazine Approved, Investigational Phase 3 60-87-7 4927
36
Histamine Approved, Investigational Phase 3 51-45-6 774
37
Sumatriptan Approved, Investigational Phase 3 103628-46-2 5358
38
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
39
Propranolol Approved, Investigational Phase 3 525-66-6 4946
40
Caffeine Approved Phase 3 58-08-2 2519
41
Angiotensin II Approved, Investigational Phase 2, Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
42
Candesartan cilexetil Approved Phase 2, Phase 3 145040-37-5 2540
43
Rizatriptan Approved Phase 3 144034-80-0, 145202-66-0 5078
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
46
Eletriptan Approved, Investigational Phase 3 143322-58-1 77993
47
Ergotamine Approved Phase 3 113-15-5 8223
48
Dihydroergotamine Approved, Investigational Phase 3 6190-39-2, 511-12-6 10531
49
Candesartan Experimental Phase 2, Phase 3 139481-59-7 2541
50 Antihypertensive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
3 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
4 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
5 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
6 Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase. Recruiting NCT03689361 Phase 4
7 A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura. Unknown status NCT00283738 Phase 2, Phase 3
8 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
9 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
10 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
11 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
12 Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache Completed NCT00449540 Phase 3
13 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
14 A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00131443 Phase 2, Phase 3 Topiramate
15 Effect of Catheter Ablation on the Prevalence, Clinical Manifestation and MRI Findings of Migraine in AF Patients With or Without a Previous History of Migraine Completed NCT01391091 Phase 3
16 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
17 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
18 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
19 Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches Completed NCT00122278 Phase 3 Dexamethasone
20 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Active, not recruiting NCT03901482 Phase 3 Dihydroergotamine;Placebos
21 An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Not yet recruiting NCT04406649 Phase 3 Dihydroergotamine
22 Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial Terminated NCT00267371 Phase 3 Medical management/current medications per standard of care by personal physician.
23 A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura Unknown status NCT00877838 Phase 2 NXN-188;Placebo
24 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
25 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
26 A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura Completed NCT00332007 Phase 2 Tonabersat;Placebo
27 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
28 An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine Completed NCT00158002 Phase 2 Topiramate
29 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
30 A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura Completed NCT00920686 Phase 2 NXN-188;placebo;sumatriptan succinate
31 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
32 Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues. Completed NCT02259075 Phase 1, Phase 2 Botulinum Toxin Type A
33 Investigator-Initiated, Proof-of-Concept, Phase 2, Randomized Controlled Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen (LDNA) Combination and Its Individual Components in the Acute Treatment of Migraine Completed NCT03061734 Phase 2 Naltrexon/Acetaminophen;Naltrexone/Acetaminophen-High Dose;Naltrexone Alone (regular dose);Acetaminophen Alone;Matching Placebo
34 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
35 Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura Not yet recruiting NCT04063540 Phase 2 Amiloride;Placebos
36 Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial) Terminated NCT00505570 Phase 2
37 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
38 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
39 A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura Unknown status NCT00893594 sumatriptan with naprosyn;placebo
40 Functional MRI and MRA in Migraine With Aura Unknown status NCT01388894
41 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
42 Identification of Inflammatory Markers in Migraine Patients Unknown status NCT00969995
43 Inflammatory Markers Identification in Migraine Patients Unknown status NCT01618201
44 Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies Unknown status NCT02196532
45 Modulation of the Excitability of the Occipital Cerebral Cortex Using Topiramate Unknown status NCT00286923 Topiramate
46 Open, Randomised, Multi-Centre, Cross-Over Study to Investigate the Efficacy of the Migraid Device Compared With No Device Treatment in the Acute, Early Treatment of Migraine With Typical Aura Completed NCT00126035
47 Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins Completed NCT02047695
48 Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients Completed NCT04012047 Levcromakalim;Saline
49 Partial Rebreathing in the Treatment of Migraine With Aura Completed NCT03472417
50 The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function. Completed NCT02253004 Early Phase 1 Cilostazol;Placebo

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Genetic Tests for Migraine with Aura

Anatomical Context for Migraine with Aura

MalaCards organs/tissues related to Migraine with Aura:

40
Brain, Cortex, Endothelial, Testes, Heart, Eye, Occipital Lobe

Publications for Migraine with Aura

Articles related to Migraine with Aura:

(show top 50) (show all 2224)
# Title Authors PMID Year
1
Assessment of cardiac mechanics and biomarkers during headache attack in migraine patients with aura: a prospective study. 61
32253565 2020
2
A Novel Heterozygous Variant in Exon 19 of NOTCH3 in a Saudi Family with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. 61
32414585 2020
3
Diagnostic and therapeutic aspects of hemiplegic migraine. 61
32430436 2020
4
Cerebral vascular reactivity and the migraine-stroke relationship: A narrative review. 61
32407982 2020
5
Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis. 61
32293721 2020
6
Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. 61
32515815 2020
7
Extra-Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. 61
32239542 2020
8
Preference for Lighting Chromaticity in Migraine With Aura. 61
32282067 2020
9
Migraine and Ischemic Stroke: Deciphering the Bidirectional Pathway. 61
32348103 2020
10
Migraine and risk of stroke. 61
32217787 2020
11
Genetics of migraine aura: an update. 61
32503413 2020
12
Patent foramen ovale. 61
32299831 2020
13
Norethisterone and its acetate - what's so special about them? 61
32398290 2020
14
The Profile and Prognosis of Youth With Status Migrainosus: Results From an Observational Study. 61
32031255 2020
15
Altered functional properties of a missense variant in the TRESK K+ channel (KCNK18) associated with migraine and intellectual disability. 61
32394190 2020
16
Subdiagnosis, but not presence of vestibular symptoms, predicts balance impairment in migraine patients - a cross sectional study. 61
32448118 2020
17
Migraine Aura: Updates in Pathophysiology and Management. 61
32430657 2020
18
Migraine and Ischemic Stroke in Women. A Narrative Review. 61
32246455 2020
19
Evaluation of simple inflammatory blood parameters in patients with migraine. 61
31758522 2020
20
Multiple Cranial Nerve Blocks as an Alternative Preventative Therapy for Chronic Migraine. 61
32232842 2020
21
A familial t(4;8) translocation segregates with epilepsy and migraine with aura. 61
32315120 2020
22
A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks. 61
31537108 2020
23
Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. 61
32056462 2020
24
Migraine and Arterial Stiffness in the Brazilian Longitudinal Study of Adult Health: ELSA-Brasil. 61
31907516 2020
25
Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura. 61
31994720 2020
26
Reversible Lesion of the Corpus Callosum in a Patient With Migraine With Aura: A Case Study. 61
32048282 2020
27
Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. 61
31645113 2020
28
Neuromelanin Locus Coeruleus MRI Contrast in Migraine With Aura. 61
32065391 2020
29
Pyridoxine, folate and cobalamin for migraine: A systematic review. 61
32279306 2020
30
Psychiatric Comorbidities in Patients with Migraine in a Tertiary Hospital. 61
32335598 2020
31
Subjective cognitive complaints and migraine characteristics: A cross-sectional study. 61
31856293 2020
32
Temporal instability of salience network activity in migraine with aura. 61
31815918 2020
33
Relationship between migraine headache and hematological parameters. 61
32347450 2020
34
Tracking the Migraine Cycle Using Visual Tasks. 61
32365776 2020
35
Migraine With Aura as Early Disease Marker in Hereditary Dutch-Type Cerebral Amyloid Angiopathy. 61
32114932 2020
36
Acute and chronic ischemia in the bilateral cerebellar border zones in patient with migraine with associated diffusion weighted imaging findings. 61
31864197 2020
37
Effect of genetic liability to migraine on coronary artery disease and atrial fibrillation: a Mendelian randomization study. 61
31661179 2020
38
Migraine with Aura as a Stroke Mimic. 61
31657289 2020
39
Psychosocial repercussion of migraine: is it a stigmatized disease? 61
32172402 2020
40
Anger and impulsiveness in migraine patients with and without aura. 61
32024445 2020
41
Migraine, headache, and mortality in women: a cohort study. 61
32183686 2020
42
Changes in face and face pareidolia processing in patients with migraine: an ERP study. 61
31940235 2020
43
Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study. 61
31769041 2020
44
Clinical features of right-to-left shunt in the different subgroups of migraine. 61
32011802 2020
45
Enhanced pre-ictal cortical responsivity in migraine patients assessed by visual chirp stimulation. 61
32188264 2020
46
Reversible sulcal FLAIR hyperintensity on MRI in a migraine patient with aura. 61
31890062 2020
47
A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks. 61
31660762 2020
48
Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research. 61
31965576 2020
49
The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. 61
32093657 2020
50
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. 61
31755111 2020

Variations for Migraine with Aura

ClinVar genetic disease variations for Migraine with Aura:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FLNA GRCh37/hg19 Xq28(chrX:153575976-153586768)copy number loss Pathogenic 523300 X:153575976-153586768
2 EMD , FLNA GRCh37/hg19 Xq28(chrX:153588672-153609996)copy number gain Pathogenic 523301 X:153588672-153609996
3 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg)SNV Pathogenic 812745 19:15302816-15302816 19:15192005-15192005
4 NOTCH3 NM_000435.3(NOTCH3):c.1162T>C (p.Cys388Arg)SNV Likely pathogenic 812743 19:15300114-15300114 19:15189303-15189303
5 NOTCH3 NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser)SNV Likely pathogenic 812744 19:15300140-15300140 19:15189329-15189329
6 DGUOK NM_080916.3(DGUOK):c.65C>T (p.Pro22Leu)SNV Uncertain significance 523554 rs757962437 2:74154102-74154102 2:73926975-73926975
7 DGUOK NM_080916.3(DGUOK):c.278G>A (p.Gly93Glu)SNV Uncertain significance 523553 rs1553403624 2:74173868-74173868 2:73946741-73946741

Expression for Migraine with Aura

Search GEO for disease gene expression data for Migraine with Aura.

Pathways for Migraine with Aura

GO Terms for Migraine with Aura

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.17 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 KCNK18
2 plasma membrane GO:0005886 10.1 SLC6A4 SLC6A3 SCN1A PRRT2 NOTCH3 KCNK18
3 integral component of plasma membrane GO:0005887 10.02 SLC6A4 SLC6A3 KCNK18 HTR2C HTR1D HTR1B
4 dendrite GO:0030425 9.83 HTR2C HTR1D HTR1B DRD2 CACNA1A
5 neuronal cell body GO:0043025 9.8 SLC6A3 SCN1A FLNA CACNA1A ATP1A2
6 synapse GO:0045202 9.61 SLC6A4 PRRT2 MTHFR HTR2C HTR1D DRD2
7 integral component of postsynaptic membrane GO:0099055 9.54 SLC6A4 SLC6A3 DRD2
8 dopaminergic synapse GO:0098691 9.46 SLC6A3 DRD2
9 serotonergic synapse GO:0099154 9.16 SLC6A4 HTR1B
10 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 SLC6A3 PRRT2 HTR1B DRD2

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.82 SLC6A3 HTR1B DRD2
2 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 HTR2C HTR1D HTR1B
3 response to pain GO:0048265 9.65 DBH CACNA1A
4 response to iron ion GO:0010039 9.65 SLC6A3 DRD2
5 negative regulation of cytosolic calcium ion concentration GO:0051481 9.65 DRD2 ATP1A2
6 chemical synaptic transmission GO:0007268 9.65 HTR2C HTR1D HTR1B DBH CACNA1A
7 prepulse inhibition GO:0060134 9.64 SLC6A3 DRD2
8 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 HTR1B DRD2
9 behavioral response to ethanol GO:0048149 9.63 DRD2 DBH
10 visual learning GO:0008542 9.63 DRD2 DBH ATP1A2
11 behavior GO:0007610 9.62 HTR2C HTR1B
12 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 9.62 HTR1B CACNA1A
13 neurotransmitter biosynthetic process GO:0042136 9.61 SLC6A4 SLC6A3
14 G protein-coupled receptor internalization GO:0002031 9.61 HTR1B DRD2
15 response to cocaine GO:0042220 9.61 SLC6A3 HTR1B DRD2
16 neurotransmitter uptake GO:0001504 9.6 SLC6A3 ATP1A2
17 neuromuscular process controlling posture GO:0050884 9.59 SCN1A PRRT2
18 regulation of behavior GO:0050795 9.58 HTR1D HTR1B
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 FLNA DRD2
20 response to nicotine GO:0035094 9.58 SLC6A3 DRD2 ATP1A2
21 dopamine catabolic process GO:0042420 9.57 SLC6A3 DBH
22 adenohypophysis development GO:0021984 9.56 SLC6A3 DRD2
23 monoamine transport GO:0015844 9.55 SLC6A4 SLC6A3
24 neuron-neuron synaptic transmission GO:0007270 9.54 DRD2 CACNA1A
25 feeding behavior GO:0007631 9.54 HTR2C HTR1B DRD2
26 hyaloid vascular plexus regression GO:1990384 9.52 SLC6A3 DRD2
27 drinking behavior GO:0042756 9.51 HTR1B DRD2
28 adult walking behavior GO:0007628 9.5 SCN1A DRD2 CACNA1A
29 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.48 HTR1D HTR1B
30 locomotory behavior GO:0007626 9.46 SLC6A3 HTR2C DRD2 DBH
31 vasoconstriction GO:0042310 9.13 SLC6A4 HTR1D HTR1B
32 response to drug GO:0042493 9.1 SLC6A4 SLC6A3 MTHFR HTR2C HTR1B DRD2

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.54 HTR2C HTR1D HTR1B
2 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A4 SLC6A3
3 dopamine binding GO:0035240 9.4 SLC6A3 DRD2
4 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR2C HTR1D HTR1B
5 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A4 SLC6A3
6 voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels GO:0099626 9.26 HTR1B CACNA1A
7 serotonin binding GO:0051378 9.26 SLC6A4 HTR2C HTR1D HTR1B
8 drug binding GO:0008144 9.1 SLC6A3 HTR2C HTR1B DRD2 ATP1A2 ACE

Sources for Migraine with Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....